These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22542492)

  • 1. Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders.
    Tatara A; Shimizu S; Shin N; Sato M; Sugiuchi T; Imaki J; Ohno Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):252-9. PubMed ID: 22542492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonergic modulation of extrapyramidal motor disorders in mice and rats: role of striatal 5-HT3 and 5-HT6 receptors.
    Ohno Y; Imaki J; Mae Y; Takahashi T; Tatara A
    Neuropharmacology; 2011; 60(2-3):201-8. PubMed ID: 20813116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-HT1A agonist alleviates serotonergic potentiation of extrapyramidal disorders via postsynaptic mechanisms.
    Shimizu S; Mizuguchi Y; Tatara A; Kizu T; Andatsu S; Sobue A; Fujiwara M; Morimoto T; Ohno Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():86-91. PubMed ID: 23838274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice.
    Shimizu S; Mizuguchi Y; Sobue A; Fujiwara M; Morimoto T; Ohno Y
    J Pharmacol Sci; 2015 Apr; 127(4):439-45. PubMed ID: 25850380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist.
    Ohno Y; Okano M; Imaki J; Tatara A; Okumura T; Shimizu S
    Pharmacol Biochem Behav; 2010 Aug; 96(2):175-80. PubMed ID: 20460137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of alpha2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders.
    Imaki J; Mae Y; Shimizu S; Ohno Y
    Neurosci Lett; 2009 Apr; 454(2):143-7. PubMed ID: 19429072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonergic involvement in haloperidol-induced catalepsy.
    Neal-Beliveau BS; Joyce JN; Lucki I
    J Pharmacol Exp Ther; 1993 Apr; 265(1):207-17. PubMed ID: 8386235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haloperidol-induced catalepsy: a model for screening antidepressants effective in treatment of depression with Parkinson's disease.
    Khisti RT; Mandhane SN; Chopde CT
    Indian J Exp Biol; 1997 Dec; 35(12):1297-301. PubMed ID: 9567763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potency and efficacy of anticholinergics to inhibit haloperidol-induced catalepsy in rats correlates with their rank order of affinities for the muscarinic receptor subtypes.
    Erosa-Rivero HB; Bata-García JL; Alvarez-Cervera FJ; Heredia-López FJ; Góngora-Alfaro JL
    Neuropharmacology; 2014 Jun; 81():176-87. PubMed ID: 24534110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice.
    Arora D; Mudgal J; Nampoothiri M; Mallik SB; Kinra M; Hall S; Anoopkumar-Dukie S; Grant GD; Rao CM
    Metab Brain Dis; 2018 Aug; 33(4):1045-1051. PubMed ID: 29516413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens.
    Ohno Y; Shimizu S; Imaki J; Ishihara S; Sofue N; Sasa M; Kawai Y
    Neuropharmacology; 2008 Oct; 55(5):717-23. PubMed ID: 18585397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational polypharmacy in the bipolar affective disorders.
    Post RM; Ketter TA; Pazzaglia PJ; Denicoff K; George MS; Callahan A; Leverich G; Frye M
    Epilepsy Res Suppl; 1996; 11():153-80. PubMed ID: 9294735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol.
    Yanahashi S; Hashimoto K; Hattori K; Yuasa S; Iyo M
    Brain Res; 2004 Jun; 1011(1):84-93. PubMed ID: 15140647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tryptophan and valine administration on behavioral pharmacology of haloperidol.
    Ali O; Haleem DJ; Saify ZS; Kamil N; Obaid R; Ahmed SW
    Pak J Pharm Sci; 2005 Apr; 18(2):23-8. PubMed ID: 16431394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
    Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
    Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats.
    Kleven MS; Barret-Grévoz C; Bruins Slot L; Newman-Tancredi A
    Neuropharmacology; 2005 Aug; 49(2):135-43. PubMed ID: 15996562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
    Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Afobazole decreases motor side effects induced by haloperidol].
    Seredenin SB; Garibova TA; Kuznetsova AL; Voronin MV; Iarkova MA; Voronina TA
    Eksp Klin Farmakol; 2009; 72(1):15-8. PubMed ID: 19334504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.